Search Results
Your search for all items matches 34705 pages
Showing 31201 - 31250Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma: Findings With Nivolumab and Cabozantinib
In the October 25 issue of The ASCO Post, we presented two important studies in previously treated advanced renal cell carcinoma, including the paper by Motzer et al “Nivolumab versus everolimus in advanced renal-cell carcinoma” (CheckMate 025), published in The New England Journal of Medicine,...
Updated Guidelines for Treating Stage IV NSCLC: Trying to Keep Up
In late August 2015, Gregory A. Masters, MD, and colleagues published an update to the ASCO guidelines for systemic therapy for stage IV non–small cell lung cancer (NSCLC), summarized in this issue of The ASCO Post.1 This builds on the full guidelines published in 20092 and the additional switch...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC
As reported in the Journal of Clinical Oncology by Gregory A. Masters, MD, and colleagues, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC).1 Recommendations are based on an update committee systematic review of randomized...
ACS Breast Cancer Screening Guidelines: Balancing the Benefits and Harms of Mammography
For the past 30 years, mammography screening has been one of the most contentious issues in medicine. Controversy has generally centered on the age at which to begin mammography screening (40 vs 50 years) and also, to a lesser extent, on the age at which it should stop. The recent American Cancer...
Getting the Content and the Message Right in Breast Cancer Screening Guidelines
According to recent national headlines, the American Cancer Society (ACS) now recommends that women at average risk of breast cancer should “screen later and less often.”1 While the new ACS recommendations (summarized in this issue of The ASCO Post) might initially be taken as casting doubt on the...
ACS Guideline Update on Breast Cancer Screening for Women at Average Risk
As reported in JAMA by Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, the American Cancer Society (ACS) has issued an update to its 2003 guideline on breast cancer screening for women at average risk of breast cancer.1 Robert A. Smith, PhD, of the...
How QOPI® Is Improving Oncology Care
Launched in 2002 as a pilot program to promote excellence in oncology care, the origins of ASCO’s Quality Oncology Practice Initiative (QOPI®) date as far back as 1997, when the Institute of Medicine (IOM) created a National Cancer Policy Board to assess the state of cancer care in the United...
Support the Conquer Cancer Foundation on Giving Tuesday
Giving Tuesday” is the perfect time to start your holiday giving and take part in a global movement to give back. Giving Tuesday has raised tens of millions of dollars for charities around the world since its start in 2012. Donating to the Conquer Cancer Foundation (CCF) this Giving...
New ASCO Answers Guide to Caregiving
This new ASCO Answers guide helps family caregivers better understand their role in the cancer care team. While there is no one way to be a caregiver, ASCO Answers: Caregiving is designed to help caregivers provide ongoing support as the person with cancer’s needs change. In addition to providing...
Former Conquer Cancer Foundation Grant Recipients Present Research Advances and Share Impact of CCF Grants
Of the $150 million being raised through The Campaign to Conquer Cancer, a planned $56 million will support vital research grants such as the Young Investigator Award (YIA) and Career Development Award (CDA). Over the past 30-plus years, the Conquer Cancer Foundation (CCF) has supported and...
ASCO University® Offers Resources for Palliative and Team-Based Care
ASCO University®, ASCO’s eLearning center, offers an array of courses and programs relevant to palliative care and multidisciplinary team–based cancer care. Below are descriptions of just a few of these offerings. Pain Management Released in March 2015, ASCO University’s “Pain Management Program”...
Applications Open for ASCO’s New Policy Fellowship Program
On October 15, ASCO launched a new fellowship program aimed at providing physicians with the necessary skills to shape cancer policy. ASCO is actively recruiting oncologists in the early phase of their careers that have leadership, civic, policy, or advocacy experience, and a keen interest in...
TAPUR: ASCO’s First Clinical Trial Addresses Critical Gaps in Understanding of and Access to Targeted Therapies
ASCO is preparing to expand the boundaries of precision medicine with the launch of its first clinical trial. At a press briefing during the 2015 ASCO Annual Meeting, the Society formally announced its plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study. At a time when...
The Bridge Project Receives $20 Million Gift From the Commonwealth Foundation for Cancer Research
The Commonwealth Foundation for Cancer Research has pledged $20 million to the Bridge Project, a collaborative research program of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) and Dana-Farber/Harvard Cancer Center (DF/HCC), to accelerate the...
City of Hope Announces New Appointments
City of Hope in Duarte, California, recently announced the following new appointments. Susanne G. Warner, MD Dr. Warner has been appointed Assistant Clinical Professor in the Department of Surgery. She received her medical degree from Texas A&M Health Science Center College of Medicine, where...
Accelerated Partial-Breast vs Whole-Breast Irradiation After Surgery for Early Breast Cancer
As reported in The Lancet by Vratislav Strnad, MD, of University Hospital Erlangen, Germany, and colleagues, 5-year results of a phase III noninferiority trial showed no difference in local relapse, disease-free survival, or overall survival with adjuvant accelerated partial breast irradiation...
Talimogene Laherparepvec for Treatment of Unresectable Cutaneous, Subcutaneous, and Nodal Melanoma Lesions
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 27, 2015, talimogene laherparepvec (Imlygic) was...
Ipilimumab in Adjuvant Treatment of Cutaneous Melanoma With Nodal Involvement
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 28, 2015, ipilimumab (Yervoy) was approved for adjuvant ...
ASH Honors Nancy Speck, PhD, and Karl Welte, MD, With 2015 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize Nancy Speck, PhD, of the University of Pennsylvania Perelman School of Medicine, and Karl Welte, MD, of Hannover Medical School, with the 2015 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
Alfred Goldberg, PhD, and Paul Richardson, MD, to Present 2015 ASH Ernest Beutler Lecture
The American Society of Hematology (ASH) will honor Alfred Goldberg, PhD, of Harvard Medical School, and Paul Richardson, MD, of Dana-Farber Cancer Institute, with the 2015 Ernest Beutler Lecture and Prize for their significant research advances in the area of proteasome inhibitors and their...
The State of Progress in Hematologic Malignancies
The number of targeted therapies approved by the U.S. Food and Drug Administration (FDA) in the treatment of a variety of cancers, especially hematologic malignancies, continues to rise. In 2014 alone, 4 of the 10 new agents directed at discrete molecular targets approved by the FDA were for blood...
Oncologists Encouraged to Learn More About Lesser-Known Heritable Gastrointestinal Cancers
The genetic basis for inherited colorectal cancer is proving to be a much bigger and more complicated “pie” than was appreciated just a few years ago, according to Michael Hall, MD, Director of Gastrointestinal Risk Assessment at Fox Chase Cancer Center, Philadelphia. “With next-generation...
Centers for Medicare & Medicaid Services Releases 2016 Medicare Physician Fee Schedule: Impact on Radiation Oncology
The final 2016 Medicare Physician Fee Schedule released October 30, 2015, by the Centers for Medicare & Medicaid Services (CMS) included cuts to radiation oncology clinics that were slightly less severe than anticipated, according to a news release issued by the American Society for Radiation...
ASH Announces Stephen S. Chung, MD, as Inaugural Jake Wetchler Foundation ASH Scholar for Pediatric Innovation Recipient
The American Society of Hematology (ASH) recently announced that Stephen S. Chung, MD, will receive the inaugural Jake Wetchler Foundation ASH Scholar Award for Pediatric Innovation for his research on the mechanisms of bone marrow failure syndromes. This work could ultimately lead to an improved...
Expert Point of View: Peter Naredi, MD, and Michael Brada, MD
Peter Naredi, MD, European CanCer Organization (ECCO) Scientific Co-Chair of the Congress, stated in a press release: “In my view, Dr. Brastianos and colleagues very elegantly show what we mean with precision medicine, how genetic profiling can support our understanding of the metastatic process,...
Actionable Targets Identified in Brain Metastases
New research shows that paired primary tumor and brain metastases share a common ancestor, but as the metastases develop in the brain, they exhibit novel genetic alterations that can activate a number of signaling pathways. More than half of the mutations represent potential therapeutic targets....
Expert Point of View: Vincent Grégoire, MD, PhD
I am actually not comfortable discussing this analysis,” said formal discussant Vincent Grégoire, MD, PhD, of the Department of Radiation Oncology, St-Luc University Hospital, Brussels, Belgium. “Instead of me you need a biostatistician. Nevertheless, I will try to address the study.” “The study...
Lenvatinib in Refractory Thyroid Cancer: Survival Benefit or Not?
In the original phase III SELECT trial, no overall survival benefit was observed for lenvatinib (Lenvima) vs placebo in progressive radioactive iodine–refractory differentiated thyroid cancer. Overall survival was a secondary endpoint in that trial. However, in an updated analysis of SELECT, which...
More Data From ECC 2015
Updated analysis of the STAMPEDE trial found no benefit for zoledronic acid in reducing deaths or skeletal-related events and confirmed the overall survival benefit of docetaxel in men with advanced hormone-sensitive prostate cancer. MDV3100, in advanced triple-negative breast cancer, found a...
Quick Takes From ECC 2015 Include New Data in Melanoma, Prostate and Breast Cancers, and Renal Cell Carcinoma
The 2015 European Cancer Congress (ECC), held recently in Vienna, represented the combined efforts of the European Cancer Organisation (ECCO), the European Society for Medical Oncology (ESMO), and other partner organisations, constituting the largest European platform for oncology education. At...
Expert Point of View: Paul M. Busse, MD, PhD
HPV-associated oropharyngeal cancer is becoming more and more prevalent. This is a ‘different beast’—distinct from the squamous cell carcinomas of the tonsil and tongue that arise from standard risk factors of tobacco and alcohol. Patients without a smoking history have an 85% to 90% cure rate,...
Evidence Mounts for Less-Intense Chemoradiation Therapy for Low-Risk Oropharyngeal Cancer
A new study shows that deintensification of chemoradiation therapy translates to excellent pathologic complete response rates in low-risk human papillomavirus (HPV)-associated oropharyngeal cancer.1 Patient-reported outcomes showed that side effects declined after 8 weeks. The hope is that these...
Howard Hochster, MD, Named President-Elect of ISGIO
The International Society of Gastrointestinal Oncology (ISGIO) has named Howard Hochster, MD, as President-Elect. Dr. Hochster, Professor of Medical Oncology; Associate Director for Clinical Sciences at Yale Cancer Center; and Director of the Gastrointestinal Cancers Program at Smilow Cancer...
Kara Kelly, MD, Will Head Joint Pediatric Hematology/Oncology Program at Roswell Park and Three Other Buffalo Institutions
Kara Kelly, MD, has been appointed as the new leader of the joint program in pediatric hematology/oncology, a partnership of Women & Children’s Hospital of Buffalo (WCHOB), Roswell Park Cancer Institute (RPCI), UBMD Pediatrics, and the University at Buffalo (UB). WCHOB, RPCI, and UB have...
Expert Point of View: Anita Mahajan, MD
This study pushes the envelope of how to use our therapies to give the most benefit to patients we otherwise wouldn’t be treating: in this case, children under the age of 3. This age group has historically been a ‘no man’s land.’ Now we see we can treat children as young as 1 year,” said Anita...
Study Lowers the Age Bar for Radiation in Children With Ependymoma
The good news is that children as young as 1 year old with the aggressive brain tumor ependymoma can be treated safely and effectively with immediate postoperative radiation therapy, according to the results of a trial presented at the 2015 ASTRO Annual Meeting.1 “Ependymoma is the third most...
Expert Point of View: David Beyer, MD
In an interview with The ASCO Post, incoming ASTRO President David Beyer, MD, provided his perspective on the use of hypofractionation in prostate cancer. Dr. Beyer is Medical Director of the Cancer Centers of Northern Arizona in Sedona. “Fractionation has been an important topic over the past few...
Hypofractionated Radiotherapy Makes Inroads as Primary Treatment of Prostate Cancer
Several studies presented at the 2015 ASTRO Annual Meeting explored the use of hypofractionation (delivering higher doses of radiation in fewer fractions) in the treatment of patients with prostate cancer. These studies found comparable outcomes in terms of efficacy and adverse events. Although...
Preston Robert Tisch Brain Tumor Center at Duke Receives $7 Million Outstanding Investigator Award
The Preston Robert Tisch Brain Tumor Center at Duke has received nearly $7 million in funding under the National Cancer Institute’s (NCI) Outstanding Investigator Award program for work on two novel immunotherapy approaches to treat brain tumors. The award recognizes the work of principal...
Genomic Test Identifies Patients With Prostate Cancer in Need of Intensified Salvage Therapy
Prostate cancer has been slow to catch up with breast cancer in terms of using biomarkers, but a new study represents progress in this regard. A genomic classifier called Decipher® provides important information that can be used to make treatment decisions for men with prostate cancer and a rising...
Third Annual JADPRO Live at APSHO Conference Attracts Over 700 Advanced Practitioners in Hematology-Oncology
Over 700 nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and other oncology health-care professionals were convened in Phoenix, Arizona, earlier this month to participate in JADPRO Live at APSHO (Advanced Practitioner Society in Hematology and Oncology), the...
Changing the Outlook for Chronic Lymphocytic Leukemia
Small-molecule inhibitors, especially ibrutinib (Imbruvica) and idelalisib (Zydelig), have greatly changed the outlook for patients with chronic lymphocytic leukemia. William G. Wierda, MD, PhD, Professor and Center Medical Director in the Department of Leukemia at The University of Texas MD...
Antoni Ribas, MD, PhD, Receives NCI Outstanding Investigator Award
UCLA Jonsson Comprehensive Cancer Center member Antoni Ribas, MD, PhD, has received a National Cancer Institute (NCI) Outstanding Investigator Award of $4.2 million in recognition of his research conducted in the development of new immunotherapies that utilize the human body’s own natural defenses ...
Genomics Now Driving Treatment of Waldenström’s Macroglobulinemia
The treatment of Waldenström’s macroglobulinemia has been greatly impacted by an understanding of its genomics, according to Steven P. Treon, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital Cancer Center, Boston. Dr. Treon brought listeners up to date on ...
Expert Point of View: Clifford Hudis, MD
Discussant Clifford Hudis, MD, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted the obvious clinical advantages of APF530 over the current standard of care. “If this drug were simply the same in price and availability, why wouldn’t you use it? It’s...
APF530 Superior to Ondansetron in Preventing Chemotherapy-Induced Nausea or Vomiting
As part of a three-drug regimen, APF530 (extended-release formulation of granisetron) has become the first 5-HT3 (5-hydroxytryptamine) receptor antagonist to demonstrate superiority over the standard of care for delayed nausea and vomiting after highly emetogenic chemotherapy. According to the...
Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD
Discussant Clifford Hudis, MD, Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted neratinib’s benefits while also advocating caution in interpreting the results due to incomplete data, the serious side effect of diarrhea, and the potentially...
Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease–free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual...
5-Year Results of GEC-ESTRO Trial of Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation: Is There Any Impact?
There is a strong rationale for the use of accelerated partial-breast irradiation: The large majority of in-breast recurrences are at or near the primary site, limiting the radiation dose to the primary site has the potential to decrease side effects, and treatment can be delivered over a shorter...
Does Low-Dose Radiation Cause Leukemia?
Data from A-bomb survivors, persons with ankylosing spondylitis and neoplasms treated with radiation therapy, and many other sources show a strong association between exposure to ionizing radiation (particles or electromagnetic waves with sufficient energy to cause an ionization such as photons and ...
